In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From Ipsen SA

European OTC Results Round-Up: Recordati, Ipsen and Venture Life

Sales & Earnings Europe

August User Fee Calendar Features Gene Therapy, Analgesics, And Of Course Oncology

Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.

US FDA Performance Tracker Drug Review

Merck & Pfizer Win English Funding For Kidney Cancer Combo

NICE says that Bavencio plus Inlyta will be made available via the Cancer Drugs Fund for advanced kidney cancer while more evidence is collected to support the combination therapy's routine use on the National Health Service.

United Kingdom Health Technology Assessment

Menarini Expands In Cancer With Radius Drug Deal

Although Elonzris, the therapy at the heart of its recent acquisition of Stemline has just been rejected in Europe, Italy's Menarini is pushing on with its expansion in oncology and is paying $30m upfront to get the rights to Radius Health's Phase III hope elacestrant.

Cancer Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Clementia Pharmaceuticals, Inc.
    • Ipsen Bioscience, Inc.
    • Sterix
    • Tercica, Inc.
    • Syntaxin Ltd.
    • OctreoPharm Sciences GmbH
    • Octagen Corporation
UsernamePublicRestriction

Register